- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02764736
Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED) (ARChIVED)
May 16, 2017 updated by: Pradhum Ram, Albert Einstein Healthcare Network
The specific aim of this trial is to determine whether initiating moderate- or high-intensity atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation and lowers average Epogen utilization.
Statin naive patients on maintenance HD will be started on 20mg atorvastatin daily for weeks and then titrated up to 40mg atorvastatin daily for an additional 12 weeks.
Patient's inflammatory markers (ferritin, CRP) and weekly Epogen usage will be monitored.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Patients will be identified and consented.
After informed consent is obtained, baseline demographic information, past medical history, dialysis specific information, and laboratory metrics (lipid profile, inflammatory markers) will be obtained from the electronic medical records.
For the first 12 weeks, all subjects will be instructed to take one 20mg atorvastatin tablet daily; atorvastatin tablets will be dispensed by the research team in 30-tablet increments every month to ensure compliance and prevent diversion.
Subjects will undergo standard-of-care hemodialysis with routine hemoglobin monitoring and Epogen titration according to the dialysis center protocol.
Every two weeks, they will be assessed by a research coordinator who will monitor for medication adverse effects (see attached patient survey) and medication compliance (pill counts) at alternating visits.
After 12 weeks, lipid profile and inflammatory markers will be rechecked or obtained from the electronic medical record.
For the subsequent 12 weeks (ie.
weeks 12-24), subjects will be instructed to take two 20mg atorvastatin tablets (40mg total) daily.
If the subject is unable to tolerate 40mg of atorvastatin daily due to medication adverse effects, they will continue to take 20mg atorvastatin daily for the remainder of the trial.
Epogen will be titrated and subjects will be monitored as above.
At the completion of the study, a lipid panel and inflammatory markers will be checked for a third time.
Epogen usage and dialysis specific information will be recorded continuously throughout the study.
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 110 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stable on Hemoglobin levels on Epogen therapy (Hgb between 9.5-11.5 for prior 3 weeks)
- No statin usage during the prior 3 months
- Complaint with hemodialysis and medications
Exclusion Criteria:
- Prior history of myocardial infarction, stroke or vascular disease
- Prior hospitalization within the past 15 days
- Prior episodes of significant bleeding (trauma, GI bleed, GU bleed, menorrhagia) in the prior 15 days
- Liver disease
- Active malignancy
- Hematologic disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: atorvastatin
Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
|
Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epoetin alfa (Epogen) utilization measured in units per week
Time Frame: 24 weeks
|
The amount of epoetin alfa, measured in units, needed to maintain a patient's hemoglobin between 11.0 and 12.0 gm/dL
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
C-reactive protein, ferritin levels
Time Frame: 24 weeks
|
24 weeks
|
Total cholesterol level, LDL level, HDL level
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2016
Primary Completion (Actual)
March 22, 2017
Study Completion (Actual)
March 22, 2017
Study Registration Dates
First Submitted
March 18, 2016
First Submitted That Met QC Criteria
May 4, 2016
First Posted (Estimate)
May 6, 2016
Study Record Updates
Last Update Posted (Actual)
May 18, 2017
Last Update Submitted That Met QC Criteria
May 16, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4802
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complication of Renal Dialysis
-
University of LuebeckUnknownComplication of Renal Dialysis | Long-Term Disorder of DialysisGermany
-
Loma Linda UniversityCompletedComplication of DialysisUnited States
-
University of Illinois at Urbana-ChampaignTerminatedComplication of DialysisUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedComplication of Peritoneal DialysisBelgium
-
Tehran University of Medical SciencesCompletedMechanical Complication of Peritoneal Dialysis CatheterIran, Islamic Republic of
-
Sunnybrook Health Sciences CentreNot yet recruitingPeritoneal Dialysis Complication | Peritoneal Dialysis Access FailureCanada
-
University of Illinois at Urbana-ChampaignCompletedEnd Stage Renal Disease | Chronic Kidney Disease | Muscle Loss | Complication of DialysisUnited States
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedEnd Stage Renal Failure on Dialysis | Complication of HemodialysisUnited States
-
Shanghai Jiao Tong University School of MedicineNot yet recruitingPeritoneal Dialysis ComplicationChina
-
University of Colorado, DenverCompleted
Clinical Trials on Atorvastatin
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Organon and CoCompleted
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRecruitingTuberculosis | Pulmonary Tuberculosis | Koch's DiseaseNigeria
-
PfizerCompletedHypertriglyceridemia | Hyperlipoproteinemia Type IVUnited States, Canada
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaboratorsNot yet recruiting
-
Organon and CoCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina